EGFR and non-small cell lung carcinoma: In the last two decades, the discovery of somatic oncogenic drivers, such as mutations in the epidermal growth factor receptor (EGFR), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) [1].